Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24253515 | 0.87 | EGFR (0.40) | EGFRPIK3CDPIK3CA | |
| SCHEMBL24253518 | 0.80 | EGFR (0.40) | EGFRPIK3CDPIK3CAIMPDH2 | |
| SCHEMBL2190665 | 0.77 | EGFR (0.48) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| SCHEMBL12410898 | 0.75 | EGFR (0.44) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| SCHEMBL24253709 | 0.74 | ALDH1A1 (0.46) | PDGFRBPDGFRA | |
| SCHEMBL3892773 | 0.74 | EGFR (0.43) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| SCHEMBL25065372 | 0.70 | EGFR (0.43) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| SCHEMBL24924336 | 0.70 | EGFR (0.44) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| SCHEMBL25065174 | 0.70 | EGFR (0.40) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| SCHEMBL23335615 | 0.70 | EGFR (0.51) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048890-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048890-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | EGFR 4824/4885PIK3CD 2458/4885PIK3CA 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.